drugset / Trial / NCT06592339

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

NCT06592339

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC
RandomizedCrossoverOpen-labelTreatment

Summary

The goal of the study is to learn what happens to levels of MK-0616 in the blood when MK-0616 is given in different forms. Researchers believe that there is no effect on a healthy person's body if MK-0616 is given in different forms.

Timeline

Start
2022-10-25
Primary completion
2022-12-29
Completion
2022-12-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Enlicitide Decanoate Unknown Oral

Indications